A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)

NCT07739199 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Non-small-cell Lung Cancer

Interventions

DRUG: BL-B01D1
DRUG: PD-1/VEGF bispecific antibody
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]